Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.
Yoh Yamaguchi; Tatsuya Yoshida; Ryoko Inaba Higashiyama; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Anticancer research, 2026年02月

Genetic Characteristics of Disease Flare After Lenvatinib Discontinuation in Patients With Thymic Carcinoma: A Brief Report.
Tomoaki Nakamura; Tatsuya Yoshida; Ken Masuda; Jun Sato; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
JTO clinical and research reports, 2025年12月

Exacerbation of cancer-associated retinopathy with anti-recoverin antibodies during atezolizumab treatment for extensive-stage small cell lung cancer: A case report.
Tomoaki Nakamura; Tatsuya Yoshida; Kohdai Kitamoto; Ken Masuda; Yi-Ning Chen; Yasushi Goto
Respiratory investigation, 2025年09月

Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer.
Kentaro Tamura; Hidehito Horinouchi; Mototaka Miyake; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Noboru Yamamoto; Yasushi Goto
Thoracic cancer, 2025年08月

Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.
Yoh Yamaguchi; Yuki Shinno; Ken Masuda; Ryo Ariyasu; Kaname Nosaki; Taiki Hakozaki; Takaaki Tokito; Shogo Nomura; Makoto Nishio; Koichi Goto; Yukio Hosomi; Koichi Azuma; Yuichiro Ohe
Current problems in cancer, 2025年06月

Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report
Mariko Nishihara; Yuki Shinno; Yoshihiro Masui; Ken Masuda; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Thoracic Cancer, 2025年06月

Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma.
Masahiro Torasawa; Tatsuya Yoshida; Kouya Shiraishi; Shigehiro Yagishita; Hanako Ono; Yuji Uehara; Jun Miyakoshi; Akiko Tateishi; Yukiko Shimoda Igawa; Ryoko Inaba Higashiyama; Akifumi Mochizuki; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Ryuji Hamamoto; Noboru Yamamoto; Shun-Ichi Watanabe; Yasushi Yatabe; Kazuhisa Takahashi; Takashi Kohno; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), 2025年04月

Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies
Hironori Satoh; Yusuke Okuma; Yuki Shinno; Ken Masuda; Yuji Matsumoto; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Lung Cancer, 2025年04月

A series of natural language processing for predicting tumor response evaluation and survival curve from electronic health records.
Toshiki Takeuchi; Hidehito Horinouchi; Ken Takasawa; Masami Mukai; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe; Mototaka Miyake; Hirokazu Watanabe; Masahiko Kusumoto; Takashi Aoki; Kunihiro Nishimura; Ryuji Hamamoto
BMC medical informatics and decision making, 2025年02月17日

Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes
Ken Masuda; Tatsuya Yoshida; Noriko Motoi; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Shun‐ichi Watanabe; Tomoaki Hoshino; Yasushi Yatabe; Yuichiro Ohe
Thoracic Cancer, 2025年01月

The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas.
Tomohiro Tanaka; Yasushi Goto; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Respiratory investigation, 2024年09月

Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Jun Miyakoshi; Tatsuya Yoshida; Jumpei Kashima; Masayuki Shirasawa; Masahiro Torasawa; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Kouya Shiraishi; Takashi Kohno; Noboru Yamamoto; Yasushi Yatabe; Takuji Suzuki; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), 2024年05月

Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Kentaro Tamura; Yusuke Okuma; Shogo Nomura; Akito Fukuda; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Journal of cancer research and clinical oncology, 2024年04月26日

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.
Yuki Takeyasu; Tatsuya Yoshida; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
JTO clinical and research reports, 2024年02月

Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Masayuki Shirasawa; Tatsuya Yoshida; Kouya Shiraishi; Naoko Goto; Shigehiro Yagishita; Tatsuya Imabayashi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Masaya Yotsukura; Yukihiro Yoshida; Kazuo Nakagawa; Katsuhiko Naoki; Takaaki Tsuchida; Ryuji Hamamoto; Noboru Yamamoto; Noriko Motoi; Takashi Kohno; Shun-Ichi Watanabe; Yuichiro Ohe
British journal of cancer, 2023年12月

Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Masayuki Shirasawa; Tatsuya Yoshida; Kouya Shiraishi; Naoko Goto; Shigehiro Yagishita; Tatsuya Imabayashi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Masaya Yotsukura; Yukihiro Yoshida; Kazuo Nakagawa; Katsuhiko Naoki; Takaaki Tsuchida; Ryuji Hamamoto; Noboru Yamamoto; Noriko Motoi; Takashi Kohno; Shun-Ichi Watanabe; Yuichiro Ohe
British journal of cancer, 2023年12月

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy.
Tomohiro Tanaka; Yasushi Goto; Masafumi Horie; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Hidehito Horinouchi; Noriko Motoi; Yasushi Yatabe; Shunichi Watanabe; Noboru Yamamoto; Yuichiro Ohe
Cancers, 2023年08月08日

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Yukiko Shimoda; Tatsuya Yoshida; Jun Miyakoshi; Masahiro Torasawa; Akiko Tateishi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Cancer immunology, immunotherapy : CII, 2023年08月

Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study.
Tomoaki Nakamura; Tatsuya Yoshida; Yuki Takeyasu; Ken Masuda; Yuki Sinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Translational lung cancer research, 2023年07月31日

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma.
Kanako Nishimatsu; Yuji Matsumoto; Jumpei Kashima; Tatsuya Imabayashi; Keigo Uchimura; Hideaki Furuse; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Takaaki Tsuchida; Yuichiro Ohe; Yasushi Yatabe
Translational lung cancer research, 2023年06月30日

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Masahiro Torasawa; Tatsuya Yoshida; Yuki Takeyasu; Yukiko Shimoda; Akiko Tateishi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Kazuhisa Takahashi; Yuichiro Ohe
Cancer medicine, 2023年06月

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Masayuki Shirasawa; Tatsuya Yoshida; Kouya Shiraishi; Ayako Takigami; Daisuke Takayanagi; Tatsuya Imabayashi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Masaya Yotsukura; Yukihiro Yoshida; Kazuo Nakagawa; Takaaki Tsuchida; Ryuji Hamamoto; Noboru Yamamoto; Noriko Motoi; Takashi Kohno; Shun-Ichi Watanabe; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), 2023年05月

Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan.
Akito Fukuda; Tatsuya Yoshida; Shigehiro Yagishita; Mika Shiotsuka; Osamu Kobayashi; Satoshi Iwata; Hitomi Umeguchi; Masatoshi Yanagida; Yasuhiro Irino; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Akinobu Hamada; Noboru Yamamoto; Yuichiro Ohe
Anticancer research, 2023年02月

Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies.
Tomohiro Tanaka; Tatsuya Yoshida; Ken Masuda; Yuki Takeyasu; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Respiratory investigation, 2023年01月

Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study.
Yoshitaka Seki; Tatsuya Yoshida; Takashi Kohno; Ken Masuda; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Kazuyoshi Kuwano; Yuichiro Ohe
Respiratory investigation, 2022年11月

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.
Mayu Ohuchi; Shigehiro Yagishita; Hitomi Jo; Kazumasa Akagi; Ryoko Inaba Higashiyama; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Yoshinori Makino; Noboru Yamamoto; Yuichiro Ohe; Akinobu Hamada
Lung cancer (Amsterdam, Netherlands), 2022年11月

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Ryoko Inaba Higashiyama; Tatsuya Yoshida; Shigehiro Yagishita; Mayu Ohuchi; Naomi Sakiyama; Masahiro Torasawa; Masayuki Shirasawa; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Akinobu Hamada; Yuichiro Ohe
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022年10月

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.
Yukiko Shimoda; Ryota Shibaki; Tatsuya Yoshida; Shuji Murakami; Masayuki Shirasawa; Masahiro Torasawa; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe; Noriko Motoi
Clinical lung cancer, 2022年09月

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Yuki Shinno; Akihiko Yoshida; Ken Masuda; Yuji Matsumoto; Yusuke Okuma; Tastuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yasushi Yatabe; Yuichiro Ohe
Clinical lung cancer, 2022年07月

Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
Masahiro Torasawa; Tatsuya Yoshida; Shigehiro Yagishita; Yukiko Shimoda; Masayuki Shirasawa; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Kazuhisa Takahashi; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), 2022年05月

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib.
Yuki Takeyasu; Tatsuya Yoshida; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
JTO clinical and research reports, 2022年05月

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
Hiroshi Takumida; Hidehito Horinouchi; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe
Cancer immunology, immunotherapy : CII, 2022年03月

Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer.
Akiko Tateishi; Hidehito Horinouchi; Tatsuya Yoshida; Ken Masuda; Hitomi Jo; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe
Respiratory investigation, 2022年03月

Effect of paracentesis on the survival of patients with terminal cancer and ascites: A propensity score-weighted analysis of the East-Asian collaborative cross-cultural Study to Elucidate the Dying process
Ken Masuda; Hiroto Ishiki; Naosuke Yokomichi; Takuhiro Yamaguchi; Tetsuya Ito; Hana Takatsu; Koji Amano; Shuji Hiramoto; Toshihiro Yamauchi; Takashi Kawaguchi; Masanori Mori; Yosuke Matsuda; Takashi Yamaguchi
2022年02月04日

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
Masayuki Shirasawa; Tatsuya Yoshida; Tatsuya Imabayashi; Kae Okuma; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Takaaki Tsuchida; Noboru Yamamoto; Yuko Nakayama; Shun-Ichi Watanabe; Noriko Motoi; Yuichiro Ohe
European journal of cancer (Oxford, England : 1990), 2022年02月

Performance of Japanese patients in registrational studies.
Yasushi Goto; Sayaka Arakawa; Masayuki Shirasawa; Ryoko Higashiyama; Keisuke Baba; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Japanese journal of clinical oncology, 2022年01月03日

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005).
Jiyun Lee; Aaron C Tan; Siqin Zhou; Shinkyo Yoon; Siyang Liu; Ken Masuda; Hidetoshi Hayashi; Ullas Batra; Dong-Wan Kim; Yasushi Goto; Sze Huey Tan; Yi-Long Wu; Dae Ho Lee; Daniel S W Tan; Myung-Ju Ahn
JTO clinical and research reports, 2022年01月

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Masayuki Shirasawa; Tatsuya Yoshida; Yukiko Shimoda; Daisuke Takayanagi; Kouya Shiraishi; Takashi Kubo; Sachiyo Mitani; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Hitoshi Ichikawa; Takashi Kohno; Noboru Yamamoto; Shingo Matsumoto; Koichi Goto; Shun-Ichi Watanabe; Yuichiro Ohe; Noriko Motoi
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021年12月

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
Chie Morita; Tatsuya Yoshida; Masayuki Shirasawa; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Shigehiro Yagishita; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Noriko Motoi; Yasushi Yatabe; Yuichiro Ohe
Scientific reports, 2021年09月21日

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Masayuki Shirasawa; Tatsuya Yoshida; Daisuke Takayanagi; Kouya Shiraishi; Shigehiro Yagishita; Katsutoshi Sekine; Shintaro Kanda; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Akinobu Hamada; Takashi Kohno; Noboru Yamamoto; Shun-Ichi Watanabe; Yuichiro Ohe; Noriko Motoi
Clinical lung cancer, 2021年07月

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Ken Masuda; Hidehito Horinouchi; Midori Tanaka; Ryoko Higashiyama; Yuki Shinno; Jun Sato; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe
Journal of cancer research and clinical oncology, 2021年01月

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Ken Masuda; Hirokazu Shoji; Kengo Nagashima; Shun Yamamoto; Masashi Ishikawa; Hiroshi Imazeki; Masahiko Aoki; Takahiro Miyamoto; Hidekazu Hirano; Yoshitaka Honma; Satoru Iwasa; Natsuko Okita; Atsuo Takashima; Ken Kato; Narikazu Boku
BMC cancer, 2019年10月21日

Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma.
Ken Masuda; Hiroto Ishiki; Shunsuke Oyamada; Masaki Shimizu; Daisuke Kiuchi; Eriko Satomi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019年09月01日

Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis.
Ken Masuda; Yutaka Fujiwara; Yuki Shinno; Takaaki Mizuno; Jun Sato; Ryo Morita; Yuji Matsumoto; Shuji Murakami; Yasushi Goto; Shintaro Kanda; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Journal of thoracic disease, 2019年07月

Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Yoshiaki Zaizen; Takaaki Tokito; Ken Masuda; Koichi Azuma; Yoshiki Naito; Shingo Tsuneyoshi; Yuki Sakazaki; Norikazu Matsuo; Hidenobu Ishii; Kazuhiko Yamada; Jun Akiba; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 2018年12月01日

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Ken Masuda; Takaaki Tokito; Koichi Azuma; Eriko Yanagida; Masayuki Nakamura; Yoshiko Naito; Norikazu Matsuo; Hidenobu Ishii; Kazuhiko Yamada; Jun Akiba; Tomoaki Hoshino
Thoracic cancer, 2018年06月

Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated Gene-5 Antibody by Intensive Immunosuppressive Therapy.
Takuma Koga; Shinjiro Kaieda; Masaki Okamoto; Ken Masuda; Kyoko Fujimoto; Satoshi Sakamoto; Masayuki Nakamura; Masaki Tominaga; Tomotaka Kawayama; Kiminori Fujimoto; Tomoaki Hoshino; Hiroaki Ida
Internal medicine (Tokyo, Japan), 2018年04月01日

Dental Technicians' Pneumoconiosis.
Masaki Okamoto; Masaki Tominaga; Shigeki Shimizu; Chiyo Yano; Ken Masuda; Masayuki Nakamura; Yoshiaki Zaizen; Takashi Nouno; Satoshi Sakamoto; Mitsuru Yokoyama; Tomotaka Kawayama; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 2017年12月15日